文献速递白血病

慢性髓性白血病:2025年诊断、治疗与监测更新

Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring.
PubMed 文献 · Am J Hematol · 2024-08-02

本文综述慢性髓性白血病(CML)的诊断与治疗进展。CML以t(9;22)形成BCR::ABL1融合基因,年发病率约2例/10万,占成人新诊断白血病约15%。FDA批准伊马替尼、达沙替尼、博舒替尼和尼洛替尼四种TKI用于慢性期初治,二代/三代TKI前线治疗缓解更深更快但未延长生存,四者改善生存等效;T315I突变对现有TKI耐药,泊那替尼、阿思尼布和奥雷巴替尼除外;异基因造血干细胞移植仍是至少两种TKI失败或进展期患者的重要选择。

要点

  • CML年发病率约2例/10万,占成人新诊断白血病约15%,特征为t(9;22)形成BCR::ABL1融合基因。
  • 四种TKI(伊马替尼、达沙替尼、博舒替尼、尼洛替尼)一线治疗慢性期CML,改善生存等效。
  • 年轻高危且以无治疗缓解为目标者,可优先选择二代TKI。

核心结论

  • 四种TKI(伊马替尼、达沙替尼、博舒替尼、尼洛替尼)一线治疗慢性期CML若以改善生存为目标则等效。
  • 年轻高危且以诱导无治疗缓解为目标者,二代TKI可能更受青睐。
  • T315I突变对现有TKI耐药,泊那替尼、阿思尼布和奥雷巴替尼除外。
  • 异基因造血干细胞移植仍是至少两种TKI失败(因耐药)的慢性期CML及所有进展期患者的重要治疗选择。
  • 对所有TKI失败后细胞遗传学复发的老年患者,继续每日最有效/毒性最低的TKI(联合或不联合非TKI抗CML药物)可维持长期生存。

研究设计与样本

  • 综述,汇总CML诊断、一线治疗、挽救治疗及监测的当前证据。

主要发现

  • CML年发病率为2例/10万,约占成人新诊断白血病15%。
  • 二代和三代TKI一线治疗慢性期CML的临床试验报告缓解更深更快,但未延长生存。
  • 二代和三代TKI具有独特药理学特征和缓解模式,与患者合并症、经济状况、疾病分期及BCR::ABL1突变状态相关。
  • T315I「守门员」突变对现有TKI均耐药,泊那替尼、阿思尼布和奥雷巴替尼除外。
  • 对所有TKI失败后细胞遗传学复发的老年患者,继续每日最有效/毒性最低TKI(联合或不联合羟基脲、高三尖杉酯碱、阿扎胞苷、地西他滨、阿糖胞苷等非TKI抗CML药物)可维持长期生存。

关键数值与推荐

  • CML特征为t(9;22)(q34;q11.2),即9q34的ABL1基因与22q11.2的BCR基因融合,形成BCR::ABL1融合癌基因。
  • FDA批准伊马替尼、达沙替尼、博舒替尼和尼洛替尼用于新诊断慢性期CML一线治疗。
  • T315I突变对现有TKI耐药,泊那替尼、阿思尼布和奥雷巴替尼除外。

临床怎么用

  • 以改善生存为目标时,四种一线TKI等效,可选用伊马替尼、达沙替尼、博舒替尼或尼洛替尼。
  • 年轻高危且以无治疗缓解为目标者,可优先选择二代TKI。
  • T315I突变患者可考虑泊那替尼、阿思尼布或奥雷巴替尼。
  • 至少两种TKI失败(因耐药)的慢性期CML及所有进展期患者,异基因造血干细胞移植仍是重要治疗选择。
  • 对所有TKI失败后细胞遗传学复发的老年患者,可继续每日最有效/毒性最低的TKI,联合或不联合非TKI抗CML药物。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

DISEASE OVERVIEW: Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm with an annual incidence of two cases/100 000. It accounts for approximately 15% of newly diagnosed cases of leukemia in adults. DIAGNOSIS: CML is characterized by a balanced genetic translocation, t(9;22) (q34;q11.2), involving a fusion of the Abelson murine leukemia (ABL1) gene from chromosome 9q34 with the breakpoint cluster region (BCR) gene on chromosome 22q11.2. This rearrangement is known as the Philadelphia chromosome. The molecular consequence of this translocation is the generation of a BCR::ABL1 fusion oncogene, which in turn translates into a BCR::ABL1 oncoprotein. FRONTLINE THERAPY: Four tyrosine kinase inhibitors (TKIs), imatinib, dasatinib, bosutinib, and nilotinib, are approved by the United States Food and Drug Administration (FDA) for first-line treatment of newly diagnosed CML in the chronic phase (CML-CP). Clinical trials with second and third-generation TKIs in frontline CML-CP therapy reported significantly deeper and faster responses but had no impact on survival prolongation, likely because of their potent efficacy and the availability of effective TKIs salvage therapies for patients who have a cytogenetic relapse with frontline TKI therapy. All four TKIs are equivalent if the aim of therapy is to improve survival. In younger patients with high-risk disease and in whom the aim of therapy is to induce a treatment-free remission status, second-generation TKIs may be favored. SALVAGE THERAPY: For CML post-failure on frontline therapy, second-line options include second and third-generation TKIs. Although potent and selective, these TKIs exhibit unique pharmacological profiles and response patterns relative to different patient and disease characteristics, such as patients' comorbidities and financial status, disease stage, and BCR::ABL1 mutational status. Patients who develop the T315I "gatekeeper" mutation display resistance to all currently available TKIs except ponatinib, asciminib, and olverembatinib. Allogeneic stem cell transplantation remains an important therapeutic option for patients with CML-CP and failure (due to resistance) of at least two TKIs and for all patients in advanced-phase disease. Older patients who have a cytogenetic relapse post-failure on all TKIs can maintain long-term survival if they continue a daily most effective/least toxic TKI, with or without the addition of non-TKI anti-CML agents (hydroxyurea, omacetaxine, azacitidine, decitabine, cytarabine, and others).

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring. Am J Hematol. 2024. PMID: 39093014. doi:10.1002/ajh.27443

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。